vimarsana.com

Page 245 - மருத்துவ ரீதியாக ஒருங்கிணைந்த வலைப்பின்னல் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How the Joe Biden presidency could impact your money

Chinese medicinal material price index up 0 02 pct

Ritter Insurance Marketing and HTA Financial Services Merge Medicare Wholesale Businesses

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ritter Insurance Marketing and HTA Financial Services Merge Medicare Wholesale Businesses Ritter Insurance MarketingJanuary 20, 2021 GMT HARRISBURG, Pa., Jan. 20, 2021 (GLOBE NEWSWIRE) Ritter Insurance Marketing (Ritter), a national leader in Medicare insurance contracts and sales technology, today announced a merger of HTA Financial Services (HTA) and Ritter’s wholesale Medicare business. Under the terms of the agreement, HTA, based in Exton, Pa., will continue to operate their retail Medicare, life, and long-term care businesses. Ritter will assume management of HTA’s wholesale Medicare business. The purchase strengthens Ritter’s Medicare sales footprint in southeastern Pennsylvania and the larger Mid-Atlantic region. As part of the merger, agents contracted to sell through HTA will receive access to Ritter’s expansive contract portfolio, industry-leading sales technology

Aptorum Group Limited: Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)

(1) Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ( Aptorum Group or Aptorum ), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced that the company, through its wholly owned subsidiary, Aptorum International Limited, has received clearance from the Public Health Agency of Canada (Health Canada) regarding the Clinical Trial Application (CTA) to commence a Phase 1 study of ALS-4, an orally administered small molecule drug intended to treat infections caused by Staphylococcus aureus including MRSA. Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. This milestone supports the transition of Aptorum Group to a clinical-stage company and reflects the potential of our scientific rigor and novel approach of our

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.